Company intelligence / Profile preview

ReveraGen BioPharma

Ownership: Private
Development stage: Phase 3

Overview

AGAMREE (vamorolone), a first-in-class dissociative steroidal anti-inflammatory drug developed by ReveraGen, received FDA approval in the US and EMA approval in Europe for the treatment of Duchenne muscular dystrophy in patients aged four years and older. Clinical trials demonstrated efficacy with a potentially improved safety profile compared to traditional corticosteroids. The company’s approach leverages a venture philanthropy model and has been supported by major grants and international collaborations[1][4][5].

Therapeutic areas: ImmunologyRare Diseases
Modalities: Small moleculeSynthetic glucocorticoid corticosteroid
Industry: Biotech

Drug pipeline

1 asset

vamorolone

Phase 3

Indications: Duchenne muscular dystrophy

Partnerships

Santhera Pharmaceuticals – global commercialization partner for vamorolone; Santhera owns worldwide rights to the drug candidate in all indications[5].Actelion Pharmaceuticals – initial option agreement/milestone payment related to future sales/distribution of vamorolone[6].

Beyond the preview

Go deeper on ReveraGen BioPharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ReveraGen BioPharma.

Explore the full profile